Andrew E Aplin

45PUBLICATIONS
134CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsPredictive and prognostic markersMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (45)

|Jul 28, 2026
A Phase II Trial of Defactinib Combined with Avutometinib in Patients with Metastatic Uveal Melanoma.

|Jul 10, 2026
S-phase targeted treatment triggers caspase-dependent lytic immunogenic cell death with pyroptotic features in cancers.

|Jun 24, 2026
Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025.

|May 21, 2026
Diacylglycerol Kinase Eta as a Novel Target in NRAS Mutant Melanoma.

|Nov 26, 2025
Pyroptosis Modulates Multiple Immune Cell Populations in Targeted Therapy-Treated Melanoma.

Nicole A Wilski-Cronin, Dan A Erkes, Timothy J Purwin

|Nov 05, 2025
Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models.

Connor A Ott, Timothy J Purwin, Pan-Yu Chen

Pageof 8

Frequent Collaborators

17 joint publications

Timothy J Purwin

9 joint publications

Nicole Wilski

7 joint publications

Vivian Chua

7 joint publications

Inna Chervoneva